We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Adding MetLife (MET) to Your Portfolio Makes Sense
Read MoreHide Full Article
MetLife, Inc. (MET - Free Report) is well-placed for growth on the back of its strategic divestitures and a strong risk-based capital position.
The company even boasts a favorable earnings surprise history, having outshined the Zacks Consensus Estimate in all the trailing four quarters, the average being 9.8%. This also vouches for the company’s operating excellence.
The stock carries an impressive VGM Score of B. Here V stands for Value, G for Growth and M for Momentum with the score being a weighted combination of all three factors.
Its return on equity — a profitability measure — stands at 10.2%, better than its industry's average of 7.9%.
The company’s revenue stream has been gaining since 2017 after it suffered a decline in 2015 and 2016. Revenues are expected to grow in 2019 on the back of sales uptick in Asia and EMEA plus higher operating premiums, fees and other revenues in its Group Benefits segment.
MetLife has been constantly making efforts to restructure its business for the past many years, focusing on businesses with growth potential. One of the most significant steps taken in this direction was the separation of its U.S. Retail business named BrightHouse Financial, which was completed in 2018. This sale freed the company from a capital-intensive business. Moreover, the divestiture closed the company’s UK Wealth Management business and MetLife Afore, S.A. de C.V. and its pension fund management business in Mexico. Thus, these strategic moves will reduce the vulnerability of MetLife and ensure more free cash flow over the long term.
MetLife has a strong risk-based capital position, sufficient liquidity and a low debt ratio. Its solid free cash flow has allowed it to buy back more than $10 billion of common shares over the last five years and hike its dividend, seeing a CAGR of 12% since 2011. The company targets to return 65-75% of earnings over a two-year period (2019-2021). The Zacks Consensus Estimate for current-year earnings per share is pegged at $5.61, indicating an increase of 4.1% on revenues of $64.6 billion from the year-ago reported figures.
For 2020, the Zacks Consensus Estimate for earnings per share stands at $6.08 on $66.6 billion revenues, implying a respective 8.4% and 3.1% rise from the prior-year reported numbers.
Shares of this Zacks Rank #2 (Buy) company have gained 5.7% in a year’s time, outperforming its industry’s growth of 0.4%.
Other Stocks to Consider
Investors interested in the same space might also take a look at some other top-ranked stocks like Aflac Incorporated (AFL - Free Report) , MGIC Investment Corporation (MTG - Free Report) and Kemper Corporation (KMPR - Free Report) .
Aflac provides voluntary supplemental health and life insurance products. It delivered average four-quarter positive surprise of 7.1% and sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
MGIC Investment Corporation provides private mortgage insurance, other mortgage credit risk management solutions and ancillary services in the United States. It came up with average four-quarter beat of 23.4% and has a Zacks Rank of 1.
Kemper Corporation offers property and casualty, and life and health insurance to individuals and businesses in the United States. The company has a Zacks Rank of 2 and managed to pull off average four-quarter beat of 12.1%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
Why Adding MetLife (MET) to Your Portfolio Makes Sense
MetLife, Inc. (MET - Free Report) is well-placed for growth on the back of its strategic divestitures and a strong risk-based capital position.
The company even boasts a favorable earnings surprise history, having outshined the Zacks Consensus Estimate in all the trailing four quarters, the average being 9.8%. This also vouches for the company’s operating excellence.
The stock carries an impressive VGM Score of B. Here V stands for Value, G for Growth and M for Momentum with the score being a weighted combination of all three factors.
Its return on equity — a profitability measure — stands at 10.2%, better than its industry's average of 7.9%.
The company’s revenue stream has been gaining since 2017 after it suffered a decline in 2015 and 2016. Revenues are expected to grow in 2019 on the back of sales uptick in Asia and EMEA plus higher operating premiums, fees and other revenues in its Group Benefits segment.
MetLife has been constantly making efforts to restructure its business for the past many years, focusing on businesses with growth potential. One of the most significant steps taken in this direction was the separation of its U.S. Retail business named BrightHouse Financial, which was completed in 2018. This sale freed the company from a capital-intensive business. Moreover, the divestiture closed the company’s UK Wealth Management business and MetLife Afore, S.A. de C.V. and its pension fund management business in Mexico. Thus, these strategic moves will reduce the vulnerability of MetLife and ensure more free cash flow over the long term.
MetLife has a strong risk-based capital position, sufficient liquidity and a low debt ratio. Its solid free cash flow has allowed it to buy back more than $10 billion of common shares over the last five years and hike its dividend, seeing a CAGR of 12% since 2011. The company targets to return 65-75% of earnings over a two-year period (2019-2021).
The Zacks Consensus Estimate for current-year earnings per share is pegged at $5.61, indicating an increase of 4.1% on revenues of $64.6 billion from the year-ago reported figures.
For 2020, the Zacks Consensus Estimate for earnings per share stands at $6.08 on $66.6 billion revenues, implying a respective 8.4% and 3.1% rise from the prior-year reported numbers.
Shares of this Zacks Rank #2 (Buy) company have gained 5.7% in a year’s time, outperforming its industry’s growth of 0.4%.
Other Stocks to Consider
Investors interested in the same space might also take a look at some other top-ranked stocks like Aflac Incorporated (AFL - Free Report) , MGIC Investment Corporation (MTG - Free Report) and Kemper Corporation (KMPR - Free Report) .
Aflac provides voluntary supplemental health and life insurance products. It delivered average four-quarter positive surprise of 7.1% and sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
MGIC Investment Corporation provides private mortgage insurance, other mortgage credit risk management solutions and ancillary services in the United States. It came up with average four-quarter beat of 23.4% and has a Zacks Rank of 1.
Kemper Corporation offers property and casualty, and life and health insurance to individuals and businesses in the United States. The company has a Zacks Rank of 2 and managed to pull off average four-quarter beat of 12.1%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>